Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Risk factors for community-associated multidrug-resistant Pseudomonas aeruginosa in veterans with spinal cord injury and disorder: a retrospective cohort study.

Spinal cord·2017

Same author

Differential proteomics reveals the hallmarks of seed development in common bean (Phaseolus vulgaris L.).

Journal of proteomics·2016

Same author

Integrated microscopy techniques for comprehensive pathology evaluation of an implantable left atrial pressure sensor.

Journal of histotechnology·2014

Same author

Primary sarcoma of left atrium.

British medical journal·2010

Same author

Expanded infectious diseases screening program for Hispanic transplant candidates.

Transplant infectious disease : an official journal of the Transplantation Society·2010

Same author

Delayed defibrillator lead perforation.

Pacing and clinical electrophysiology : PACE·2008

Search research articles

Related Experiment Video

Updated: May 27, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Converting enzyme inhibitors in heart failure.

M G Nicholls¹, H Ikram, M A Fitzpatrick

¹Department of Cardiology, Princess Margaret Hospital, Christchurch, New Zealand.

European Heart Journal

|June 1, 1988

Summary

Angiotensin converting enzyme (ACE) inhibitors help manage heart failure by reducing harmful hormones and improving circulation. While generally safe, potential side effects require careful monitoring and management.

More Related Videos

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Related Experiment Videos

Last Updated: May 27, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Area of Science:

Cardiology
Pharmacology
Nephrology

Background:

The renin-angiotensin system (RAS) is activated in heart failure, correlating with disease severity and diuretic use.
RAS activation contributes to hemodynamic derangement in heart failure patients.

Purpose of the Study:

To evaluate the effects of Angiotensin Converting Enzyme (ACE) inhibitors on neurohormonal levels and circulatory dynamics in heart failure.
To assess the impact of ACE inhibitors on renal function and electrolyte balance.
To discuss potential hazards and future therapeutic trends of ACE inhibitor use in cardiac conditions.

Main Methods:

Review of existing literature on ACE inhibitor therapy in heart failure.
Analysis of changes in hormone levels (angiotensin II, aldosterone, noradrenaline, vasopressin, cortisol) and electrolytes (potassium, sodium).
Evaluation of hemodynamic parameters, glomerular filtration rate, and organ blood flow.

Main Results:

ACE inhibitors reduce angiotensin II and aldosterone, potentially lowering noradrenaline, vasopressin, and cortisol.
Potassium retention is typical, with variable sodium balance depending on patient status and diuretic policy.
Circulatory dynamics generally improve, preserving blood flow to the brain, myocardium, and kidneys.

Conclusions:

ACE inhibitors offer significant benefits in managing heart failure by counteracting the activated renin-angiotensin system.
Careful management can mitigate potential hazards associated with ACE inhibitor therapy.
Future applications may include early-stage heart failure and post-myocardial infarction treatment.